当前位置:首页 >财报库 > 报告详情

安进Amgen(AMGN)2025年第一季度财报「NASDAQ」(英文版)(66页).pdf

上传人: Kell****reet 编号:653908 2025-05-20 66页 817.95KB

下载:

1、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549FORM 10-Q(Mark One)QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACTOF 1934For the quarterly period ended March 31,2025orTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACTOF 1

2、934Commission File Number:001-37702Amgen Inc.(Exact name of registrant as specified in its charter)Delaware 95-3540776(State or other jurisdiction of incorporation or organization)(I.R.S.Employer Identification No.)One Amgen Center Drive 91320-1799Thousand OaksCalifornia(Address of principal executi

3、ve offices)(Zip Code)(805)447-1000(Registrants telephone number,including area code)Securities registered pursuant to Section 12(b)of the Act:Title of each classTrading Symbol(s)Name of each exchange on which registeredCommon stock,$0.0001 par valueAMGNThe Nasdaq Global Select Market2.00%Senior Note

4、s due 2026AMGN26The Nasdaq Global Select MarketIndicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934during the preceding 12 months(or for such shorter period that the registrant was required to file suc

5、h reports)and(2)has been subject to such filingrequirements for the past 90 days.Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T(232.405 of this chapter)during the preceding 1

6、2 months(or for such shorter period that the registrant was required to submit suchfiles).Yes No Indicate by check mark whether the registrant is a large accelerated filer,an accelerated filer,a non-accelerated filer,a smaller reporting company,or anemerging growth company.See the definitions of“lar

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
本文是Amgen Inc.(安进公司)2025年第一季度10-Q报告的摘录,主要内容包括: 1. Amgen报告了2025年第一季度的财务业绩,总收入为81.49亿美元,净利润为17.3亿美元。 2. Amgen的主要产品包括Prolia、Repatha、XGEVA、ENBREL、Evenity、Otezla、TEPEZZA、BLINCYTO、Aranesp、KYPROLIS、Nplate、TEZSPIRE、Vectibix、KRYSTEXXA等。 3. Amgen的债务总额为589.45亿美元,长期债务为540.13亿美元。 4. Amgen的股东权益总额为62.07亿美元,每股基本收益为3.22美元。 5. Amgen的资产负债表显示,截至2025年3月31日,现金及现金等价物为88.1亿美元。 6. Amgen的财务报表附注中提到了对Otezla无形资产的减值,以及对BeiGene投资的价值变动。 7. Amgen的财务报表附注中还提到了与税务相关的争议,包括美国国税局对Amgen的审计。 8. Amgen的股票回购计划和股息政策也有所提及。
2025年第一季度,安进公司净利润是多少? 安进公司2025年第一季度每股收益是多少? 安进公司2025年第一季度研发费用是多少?
客服
商务合作
小程序
服务号
折叠